Ruti Aga banned for six years: a family member forged the prescription, and a glucocorticoid case ended a career

Ethiopian marathon runner Ruti Aga has been banned for six years, the Athletics Integrity Unit (AIU) said in a statement on Thursday. The 32-year-old was sanctioned for two separate violations: the presence of the prohibited substance methylprednisolone, and tampering with the investigation by submitting a forged medical prescription. Her provisional suspension ran from 10 September, and the full ban is backdated to the same date. This is less a doping story than a governance story: a knee injury, an informal medical support network and one fabricated document combined to end an elite career. The arithmetic: two years plus four years The structure is straightforward — two years for the presence violation and four years for tampering, totalling six. That arithmetic tells us a great deal. A two-year sanction is the typical outcome when the substance is a Specified Substance and intent to enhance performance is not proven, meaning the panel accepted she did not take the drug in order to cheat. The separate four-year sanction shows the panel treated the document fraud as fully culpable conduct. The two add up to six, and that is the tragedy of the case: the forged paperwork cost her far more than the substance did. Methylprednisolone is a glucocorticoid, not a steroid Much of the media coverage has described methylprednisolone as a 'prohibited steroid'. Technically that is wrong. Methylprednisolone is a glucocorticoid, listed under class S9 of the WADA Prohibited List — not class S1, which covers anabolic steroids. The distinction is not semantic. S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally or rectally. A therapeutic knee injection given out of competition is entirely legal; a violation arises only if residues are present in a sample taken in-competition. The entire case therefore hinged on route of administration and timing relative to the race, not on 'steroid use'. In road running the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. That detail matters because a documented, properly timed treatment would have given her a legitimate defence. What happened According to the available information, Aga's sample was collected after she won a half marathon in China in March. The report does not name the race, disclose her finishing time or describe the strength of the field, so no performance conclusion can responsibly be drawn. What is clear is that it was an international-level road race with an elite women's field and AIU testing — and that appearance fees and prize money were at stake. Aga's defence cited a knee injury, with the injection described as part of treatment. From a sports-medicine standpoint that is not implausible: knee synovitis and joint problems are common in high-volume distance runners, and intra-articular glucocorticoid injection is standard practice. The problem was that no genuine record existed to support the claim. The forged prescription: three separate failures What the AIU investigation uncovered was not a simple error. First, the clinic named on the prescription did not exist. Second, the person who wrote it was a family member with no medical registration. Third, that person claimed to have used an old prescription pad from a former workplace — and the clinic explicitly disowned the claim. Three independent verifications, three failures. It is the signature of an athlete operating without a credentialed team physician. The tampering sanction came from an interview, not just a document The four-year tampering sanction rests partly on statements made under questioning, not solely on the paper trail. Language and translation conditions in AIU interviews with East African athletes have been a recurring point of contention and may be raised on appeal, though the documentary evidence of forgery will be hard to overturn. Career impact: effectively over at 32 Aga is 32. A six-year ban running from 10 September means a return at roughly 38. Ethiopian women's marathon depth is so extreme that a 38-year-old with a doping record is essentially unselectable for the national team. The 2028 Olympic cycle has gone entirely. In practical terms this is not a six-year ban; it is the end of a career. What survives The ban affects future results. The report does not state the scope of disqualification, but standard practice voids the result and prize money from the competition where the sample was collected. Earlier achievements — the 2026 Tokyo Marathon title and three second-place finishes at World Marathon Majors — are not automatically annulled absent a finding of earlier use. Unfortunately, that record will now always be read with an asterisk attached. The real root cause: a medical support failure It is easy to treat this as one athlete's moral lapse, but the picture is wider. The 'doctor' was a family member, not a registered team physician. No record of medical advice, no application for a Therapeutic Use Exemption, no accounting for route or timing. That informal medical arrangement is not an exception in East African road-running camps. Injured runners face intense pressure from appearance-fee and availability contracts, and glucocorticoids are the cheapest, most accessible way to mask pain. The forged prescription is a symptom of that gap, not its origin. China's label circuit and the testing economy The case is also emblematic because it connects to the Asian race circuit that serves as a key income stream for East African marathoners between the Majors: few races, large appearance fees, low risk. But the AIU's testing machinery is now most active at exactly that tier. Where the money is heaviest, scrutiny is sharpest — and that collision will produce more cases. The enforcement frontier is shifting A pattern recurs in AIU road-running cases: first a substance violation, then a fabricated or altered explanation. Enforcement is moving from detection towards document verification. In training clusters where a single informal medical network serves many athletes, clusters of such cases are likely. Aga's case is not an outlier; it is an example of a category. No measurable effect on the competition Competitively, Aga's absence does not change Ethiopia's capacity by any measurable margin. She was never a global championship medallist; her major results came at commercial-tier races. In Ethiopian women's marathon running, even a 2:18 performer is not automatically selectable. The damage is to the sport's governance reputation, not its competitive order. How the defence was destroyed Here is the bitter irony. A legitimate defence existed: genuine medical records, a clear record of the injection's date and route, and evidence that the substance had cleared before competition. Such a case could have been argued at the no-fault or no-significant-fault end, potentially attracting a reprimand or a heavily reduced period — with no tampering charge at all. By fabricating the prescription, the athlete closed off the one route that could have worked. Appeal prospects An appeal remains formally open, typically within about 21 days of the reasoned decision to the Court of Arbitration for Sport. But overturning documentary forgery is very difficult. A reduction in the sanction is unlikely; a longer legal bill and more publicity are considerably more likely. Rigour or uneven enforcement? Six years for a glucocorticoid with no proven endurance benefit is a striking outcome. The AIU will present it as evidence of rigour. Critics will cite it as evidence of disproportionate enforcement against African road runners. Both sides have arguments. What is clear is that most of the sanction is for the lie, not the substance — and that is precisely the message the agency wants to send. What remains unclear For transparency, several points must be recorded. The available report does not state the year of the March race, Aga's finishing time, the exact end date of the ban, or the scope of annulled results. It is also unclear whether her agent or management was investigated; the AIU named only the family member who wrote the prescription. The non-existent clinic, the unregistered author and the old prescription pad are all in the report, but the precise articles underpinning the sanction are not. Conclusion Ruti Aga's case is less about doping than about sports administration. A 32-year-old athlete, a chronic knee problem, informal treatment and a document that never existed produced a sanction that, by the arithmetic of age, is a career death sentence. The lesson is not only for athletes. It is for the agents, managers and national federations who still assume that medical paperwork can be written by anyone and that nobody will notice. The AIU has made clear that they will — and that the price is extracted for the lie, not the substance.